From the Journals

Concerns that low LDL-C alters cognitive function challenged in novel analysis

FROM THE JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Data do not support low LDL-C as cognitive risk factor

Moreover, this study – as well as other evidence – argues strongly against very low levels of LDL-C, regardless of how they are achieved, as a risk factor for diminished cognitive function, Dr. Ference, director of research in the division of translational therapeutics, University of Cambridge (England), said in an interview.

“There is no evidence from Mendelian randomization studies that lifelong exposure to lower LDL-C increases the risk of cognitive impairment,” he said. “This is true when evaluating lifelong exposure to lower LDL-C due to genetic variants in a wide variety of different genes or the genes that encode the target PCKS9 inhibitors, statins, or other lipid-lowering therapies.”

In other words, this study “adds to the accumulating evidence” that LDL-C lowering by itself does not contribute to an adverse impact on cognitive function despite persistent concern. This should not be surprising. Dr. Ference emphasized that there has never been strong evidence for an association.

“As I point out in the editorial, there is no biologically plausible mechanism by which reducing peripheral LDL-C should impact neurological function in any way, because the therapies do not cross the blood brain barrier, and because the nervous system produces its own cholesterol to maintain the integrity of membranes in nervous system cells,” he explained.

Dr. Lohoff reports no potential conflicts of interest. Dr. Ference has financial relationships with numerous pharmaceutical companies including those that make lipid-lowering therapies.

Pages

Recommended Reading

Hypertension heightens risk for severe COVID-19, even in the fully vaxxed
MDedge Cardiology
‘Alarming’ global rise in NAFLD
MDedge Cardiology
New update focuses on NAFLD in lean people
MDedge Cardiology
Metabolic syndrome raises dementia risk in under-60s
MDedge Cardiology
Remnant cholesterol captures residual CV risk in patients with T2D
MDedge Cardiology
For patients with peripheral artery disease, pain can be gain
MDedge Cardiology
Ezetimibe plus statin: Attractive bypass to high-dose monotherapy
MDedge Cardiology
Is Lp(a) a marker for aortic calcium onset?
MDedge Cardiology
‘Staggering’ CVD rise projected in U.S., especially in minorities
MDedge Cardiology
Social isolation, loneliness tied to death, MI, stroke: AHA
MDedge Cardiology